Medanta's Q2 FY27 numbers were strong, but the more useful signal came from the new hospitals. Noida moved into positive EBITDA, developing hospitals carried a larger share of growth, and occupancy improved despite a bigger bed base. The next test is whether Medanta can repeat that ramp-up while committing capital to another large greenfield programme.

Growth came from patient volumes rather than a sharp rise in pricing

Global Health Limited, which operates the Medanta hospital network, reported Q2 FY27 revenue from operations of ₹1,469 crore, up 33.6% year on year. Operating EBITDA rose 60.2% to ₹370 crore and margin improved to 25.2% from 21.0%. PAT increased 38.3% to ₹219 crore.

The operating data explains the quarter better than the headline P&L. In-patient volumes rose 29.5%, OPD encounters increased 37.9% and occupied bed days were up 22.4%. ARPP moved only 2.7% higher to ₹2.06 lakh, while average length of stay fell to 2.89 days from 3.06 days.

So most of the growth came from putting more patients through a larger network, not from a large pricing increase. Occupancy improved to 67% even though census capacity was 17.2% higher than a year ago. That is a good sign after a period in which Medanta added beds faster than those beds could initially contribute to earnings.

Noida changed the tone of the quarter

Noida was the most important operational datapoint. The hospital reported ₹105.9 crore of revenue and ₹8.6 crore of positive operating EBITDA in Q2. In H1 FY27, revenue was ₹191.4 crore and EBITDA was ₹3.6 crore.

The absolute profit is still small. What matters is the change in direction. New hospitals carry doctors, staff and infrastructure costs well before utilisation reaches steady-state levels, so they normally dilute margins during the ramp-up phase. Medanta's FY26 annual report reflected exactly that pattern: return on capital employed had fallen as capital was invested in greenfield projects whose earnings contribution was still to come.

Noida reaching EBITDA breakeven within one year of commencing operations shows that the last expansion cycle is starting to move from investment into monetisation.

The hospital still has room to scale. Noida has 550 installed beds, of which 482 were operational at the end of September. The next leg will depend on occupancy, case mix and deeper utilisation of the clinical platform rather than another large addition to fixed infrastructure.

Lucknow, Patna and Noida are becoming a larger part of earnings

The mature cluster of Gurugram, Indore and Ranchi remains the stable base. Q2 revenue from these hospitals rose 17.8% to ₹823 crore and operating EBITDA increased 29.1% to ₹181 crore. Margin improved to 22.0% from 20.1%.

Growth was much faster in Lucknow, Patna and Noida. Revenue across this cluster increased 63.2% to ₹579 crore, while operating EBITDA more than doubled to ₹184 crore. Margin reached 31.7%, against 24.7% a year earlier.

That mix shift is encouraging. The newer hospitals are no longer adding only beds and revenue; they are contributing profit at a faster pace. Lucknow and Patna are further along the maturity curve, while Noida has only just crossed breakeven.

Other parts of the network also grew well. International patient revenue rose 30.3% to ₹99.3 crore and OPD pharmacy revenue increased 52.9% to ₹69.9 crore. Neither changes the core hospital thesis on its own, but both add revenue around the same clinical infrastructure and patient base.

Installed beds and census beds should not be mixed

Medanta had 3,811 installed beds across six operating hospitals as of September 30, 2026. For occupancy, however, the company uses census beds - beds actually available for patient use. Census capacity was 3,115 in Q2 FY27 versus 2,658 a year earlier.

The difference is important when reading the operating data. Applying the 67% occupancy figure to the 3,811 installed-bed number would overstate the amount of capacity available for patients.

Medanta added 74 beds during Q2 - 49 at Noida and 25 at Lucknow - taking H1 additions to 146 beds. This followed a much larger FY26 expansion, when 623 beds were added across the network.

The FY26 annual report sets out the broader strategy clearly: replicate Medanta's large-format, doctor-led tertiary and quaternary care model in markets where advanced healthcare capacity is still limited. The Q2 numbers suggest the existing network is absorbing new capacity reasonably quickly, but that execution record will matter even more as the next set of hospitals is built.

Ghaziabad adds another sizeable project to the pipeline

Alongside the results, Medanta's Board approved a 500-bed multi-specialty hospital in Ghaziabad. The company had acquired a 2.61-acre land parcel through an e-auction for ₹165.8 crore in September 2026. Estimated project capex is about ₹997 crore.

With Ghaziabad included, Medanta plans to add more than 3,450 beds across six greenfield projects. The other major locations are Mumbai, Pitampura, South Delhi, Guwahati and Varanasi. The Q2 investor presentation puts total planned capex at roughly ₹6,239 crore over the next four to five years, including maintenance and other growth expenditure.

That means Medanta is entering another investment-heavy period just as the last one begins to show operating leverage.

The opportunity is substantial. A larger network gives Medanta more capacity in markets where tertiary-care demand is growing and where the brand can potentially replicate its existing hub model. But each greenfield hospital carries a multi-year gestation period. Returns will depend on commissioning discipline, clinician hiring, utilisation and the pace at which each facility moves through breakeven.

The balance sheet can support the build-out, but cash generation now matters more

Medanta ended September with net cash of ₹781.5 crore. H1 operating cash flow was ₹567.8 crore and EBITDA-to-cash-flow conversion stood at 86.4%. Capex during the first half was ₹338.5 crore.

That gives the company room to fund expansion, although the next few years will be more capital intensive. Finance costs have already increased, and depreciation will rise as new assets are commissioned.

For that reason, EBITDA growth alone will not be enough to judge the next phase. Cash flow after capex, the speed of new-hospital ramp-up and the amount of capital tied up before those assets mature will be more useful indicators.

If Noida continues to improve while the established hospitals hold their margins, Medanta should be able to fund a meaningful part of the pipeline internally. Slower ramp-ups across several projects at the same time would make the balance sheet more important to the thesis.

Investor view

Q2 FY27 was a strong operating quarter for Medanta. Revenue grew 33.6%, operating EBITDA rose 60.2% and margin reached 25.2%. More importantly, patient volumes grew faster than pricing, occupancy improved on a larger bed base and Noida crossed EBITDA breakeven.

The reported PAT comparison is slightly understated by the base. Q2 FY26 included ₹16 crore of non-recurring exceptional income, while Q2 FY27 had no exceptional item. That makes the improvement in underlying profitability somewhat better than the headline 38.3% PAT growth suggests.

The investment case now rests on capital allocation as much as earnings growth. Medanta has shown that Noida can move toward breakeven quickly. It now has to repeat that execution across Ghaziabad and the rest of the greenfield pipeline without weakening cash returns.

The numbers worth watching are Noida's margin progression, occupancy as the census bed base expands, cash conversion and the pace of capex. If those stay disciplined, the new hospitals can extend the earnings runway. A slower ramp-up would weaken returns on the capital being deployed and delay the earnings contribution from the new capacity.